2. Search Result
Search Result
Results for "

early-onset

" in MedChemExpress (MCE) Product Catalog:

13

Inhibitors & Agonists

1

Peptides

1

Inhibitory Antibodies

1

Natural
Products

1

Isotope-Labeled Compounds

1

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-14905
    Uridine triacetate

    Tri-O-acetyl uridine

    		 Drug Derivative Neurological Disease
    Uridine triacetate (Tri-O-acetyl uridine) is an orally active proagent of Uridine (HY-B1449). Uridine triacetate is quickly absorbed in the gut, and is rapidly deacetylated in the circulation to yield free uridine. Uridine triacetate is used for the research of 5-fluorouracil (5-FU) and capecitabine toxicity, or early-onset cardiac or central nervous system (CNS) .
    Uridine triacetate
  • HY-126359
    1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine

    SLPC; 18:0-18:2 PC

    		 Endogenous Metabolite Cardiovascular Disease Metabolic Disease
    1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine (SLPC; 18:0-18:2 PC) is an endogenous phospholipid marker molecule in the glycerophospholipid metabolic pathway. 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine is a core component of the phospholipid bilayer of biological membranes and a key responsive lipid for radiation injury and cardiometabolic diseases. 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine constitutes the phospholipid bilayers of cell membranes and high-density lipoprotein (HDL), and regulates the core activity of lipoprotein functional homeostasis. The content of 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine in mouse serum shows a significant dose-dependent decrease with increasing ionizing radiation dose, and its level in human HDL also decreases significantly in metabolic syndrome. 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine can serve as a biological dosimeter marker for ionizing radiation injury, and is used for rapid and accurate assessment of radiation absorbed dose in exposed individuals. 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine can also act as a lipidomics research target for cardiometabolic diseases such as lipid metabolic syndrome and early-onset coronary heart disease .
    1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine
  • HY-136066
    Tauro-ω-muricholic acid sodium
    1 Publications Verification

    TωMCA sodium

    		 Endogenous Metabolite Metabolic Disease
    Tauro-ω-muricholic acid sodium (TωMCA sodium) is a bile acid released by the liver and an analog of tauro-α-muricholic acid. Tauro-ω-muricholic acid sodium is investigated as a potential marker in plasma for early-onset neonatal sepsis (EOS) and cholestasis studies
    Tauro-ω-muricholic acid sodium
  • HY-110174
    NAB2

    		α-synuclein Neurological Disease
    NAB2 is a neuroprotectant that targets the small GTPase Rab1a. NAB2 selectively binds to the GDP-bound form of Rab1a and protects multiple cell types from α-synuclein toxicity by increasing Rab1a expression. Rab1a regulates ER-to-Golgi trafficking and mediates endosomal trafficking events of the E3 ubiquitin ligase Rsp5/Nedd4. NAB2 stimulates ubiquitination of related proteins in a Nedd4-dependent manner and rescues α-synuclein-associated trafficking defects associated with early-onset Parkinson's disease .
    NAB2
  • HY-P2378
    Neuromedin U-25 (human)

    		Endogenous Metabolite Cardiovascular Disease
    Neuromedin U-25 human is the active form of neuromedin U in human. Neuromedin U-25 human inhibits glucose-stimulated insulin secretion, which leads to early-onset obesity. Neuromedin U-25 serves as vasoconstrictor in human vascular beds .
    Neuromedin U-25 (human)
  • HY-146272
    Vasopressin V2 receptor antagonist 1

    		Vasopressin Receptor Endocrinology
    Vasopressin V2 receptor antagonist 1 is a vasopressin V2 receptor (V2R) antagonist with a Ki value of 3.8 nM. Vasopressin V2 receptor antagonist 1 inhibits renal cyst formation in embryonic renal cyst models and mouse models. Vasopressin V2 receptor antagonist 1 can be used in research related to autosomal dominant polycystic kidney disease .
    Vasopressin V2 receptor antagonist 1
  • HY-178150
    WEE1-IN-14

    		Wee1 Cancer
    WEE1-IN-14 (Compound 14) is a selective WEE1 inhibitor (IC50: 0.5 nM in L-RB-FEP calculations, 1.0 nM in ADP-Glo kinase assay). Inhibition of Wee1 in cancer cells disrupts the G2-M checkpoint, removes the regulatory controls on the cell cycle, and leads to early onset of mitotic failure followed by apoptosis of tumor cells. Therefore, WEE1-IN-14 is a useful tool for studying cancer biology .
    WEE1-IN-14
  • HY-152014S
    Stearoylcarnitine-d3-1 hydrochloride

    		Isotope-Labeled Compounds Endogenous Metabolite Neurological Disease
    Stearoylcarnitine-d3-1 (hydrochloride) is deuterium labeled Stearoylcarnitine. Stearoylcarnitine, a fatty ester lipid molecule, is a human endogenous metabolite. Stearoylcarnitine acts as a metabolomics biomarker for early-onset-preeclampsia and late-onset-preeclampsia .
    Stearoylcarnitine-d3-1 hydrochloride
  • HY-106018A
    Mitemcinal fumarate

    GM 611 fumarate

    		 Motilin Receptor Others
    Mitemcinal fumarate is an oral motilium agonist. Studies in rabbits and dogs have shown that it can promote defecation without causing severe diarrhea, increase stool weight without increasing water content in the rabbit constipation model, and reduce the time to first defecation in dogs. Mitemcinal fumarate may be a constipation suppressant due to its early onset and short duration of action.
    Mitemcinal fumarate
  • HY-106018
    Mitemcinal

    GM 611

    		 Motilin Receptor Others
    Mitemcinal (GM 611) is an oral motilin receptor agonist. Studies in rabbits and dogs have shown that it can promote defecation without causing severe diarrhea, increase stool weight without increasing water content in the rabbit constipation model, and reduce the time to first defecation in dogs. Mitemcinal may be a constipation suppressant due to its early onset and short duration of action .
    Mitemcinal
  • HY-P992393
    JMT203

    		TGF-β Receptor Cancer
    JMT203 is a monoclonal antibody against GFRAL and a body weight gain inducer. JMT203 induces early-onset, sustained and progressive body weight gain in cancer cachexia. JMT203 can be used for research related to cancer cachexia .
    JMT203
  • HY-123925
    CSLP43

    		RIP kinase IAP NOD-like Receptor (NLR) Inflammation/Immunology
    CSLP43 is a selective RIPK2 and XIAP inhibitor with an IC50 of 19.9 nM against human RIPK2. CSLP43 binds to the ATP-binding pocket of RIPK2 and disrupts the interaction between RIPK2 and the BIR2 domain of XIAP or cIAP1. CSLP43 inhibits RIPK2 ubiquitination, NOD1-dependent inflammatory signaling pathways, NOD2-dependent inflammatory signaling pathways, as well as NF-κB activation associated with NOD agonists. CSLP43 is selective for the NOD1/NOD2 signaling pathway and does not inhibit the kinase activity of RIPK1 or RIPK3. CSLP43 is applicable to research related to Crohn's disease, Blau syndrome, early-onset sarcoidosis and early-onset inflammatory bowel disease .
    CSLP43
  • HY-186163
    CC-410

    		Amine N-methyltransferase Metabolic Disease
    CC-410 is a selective Nicotinamide N-methyltransferase (NNMT) inhibitor with a human IC50 value of 1.6 µM. CC-410 impairs terminal adipocyte differentiation via glucocorticoid signaling network deregulation, inhibits adipogenesis and lipid accumulation with time-sensitive activity limited to early adipogenesis stages. CC-410 can be used for the researches of early-onset obesity, glucocorticoid-induced obesity .
    CC-410

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: